Theravance Biopharma Inc
TBPH11.220USD
+0.320+2.94%
Cierre 08/04, 16:00（ET）Cotizaciones retrasadas 15 min
561.01MCap. mercado
PérdidaP/E TTM
Más Datos de Theravance Biopharma Inc Compañía
Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development, and commercialization of medicines. Its product, YUPELRI (revefenacin) inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is a prescription medicine used to treat COPD, a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Ampreloxetine, its late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension.
Información de la empresa
Símbolo de cotizaciónTBPH
Nombre de la empresaTheravance Biopharma Inc
Fecha de salida a bolsaMay 16, 2014
Director ejecutivoMr. Rick E. Winningham
Número de empleados97
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 16
DirecciónUgland House, South Church Street
CiudadGEORGE TOWN
Bolsa de valoresNASDAQ Global Market Consolidated
PaísCayman Islands
Código postalKY1-1104
Teléfono16508086000
Sitio Webhttps://www.theravance.com/
Símbolo de cotizaciónTBPH
Fecha de salida a bolsaMay 16, 2014
Director ejecutivoMr. Rick E. Winningham
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Rick E. Winningham
Mr. Rick E. Winningham
Chief Executive Officer, Director
Chief Executive Officer, Director
1.31M
-2.21%
Dr. Aine Miller
Dr. Aine Miller
Senior Vice President - Development and Head of Ireland Office
Senior Vice President - Development and Head of Ireland Office
214.99K
+0.34%
Mr. Brett A. Grimaud
Mr. Brett A. Grimaud
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
160.16K
-5.73%
Mr. Aziz Sawaf
Mr. Aziz Sawaf
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
142.13K
-6.17%
Mr. Eran Broshy
Mr. Eran Broshy
Independent Director
Independent Director
91.20K
+13.22%
Mr. Donal O'Connor
Mr. Donal O'Connor
Independent Director
Independent Director
74.20K
+16.76%
Dr. Deepika R. Pakianathan, Ph.D.
Dr. Deepika R. Pakianathan, Ph.D.
Independent Director
Independent Director
58.06K
+22.46%
Ms. Susannah Gray
Ms. Susannah Gray
Independent Chairman of the Board
Independent Chairman of the Board
42.14K
+33.82%
Mr. Jeremy T. Grant
Mr. Jeremy T. Grant
Independent Director
Independent Director
28.54K
+59.52%
Mr. Dean Jonathan (Dean) Mitchell
Mr. Dean Jonathan (Dean) Mitchell
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Rick E. Winningham
Mr. Rick E. Winningham
Chief Executive Officer, Director
Chief Executive Officer, Director
1.31M
-2.21%
Dr. Aine Miller
Dr. Aine Miller
Senior Vice President - Development and Head of Ireland Office
Senior Vice President - Development and Head of Ireland Office
214.99K
+0.34%
Mr. Brett A. Grimaud
Mr. Brett A. Grimaud
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
160.16K
-5.73%
Mr. Aziz Sawaf
Mr. Aziz Sawaf
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
142.13K
-6.17%
Mr. Eran Broshy
Mr. Eran Broshy
Independent Director
Independent Director
91.20K
+13.22%
Mr. Donal O'Connor
Mr. Donal O'Connor
Independent Director
Independent Director
74.20K
+16.76%
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
U.S.
64.38M
0.00%
Europe
0.00
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Madison Avenue Partners LP
19.02%
Weiss Asset Management
14.91%
Newtyn Management, LLC
9.51%
BlackRock Institutional Trust Company, N.A.
6.07%
Irenic Capital Management LP
5.52%
Other
44.96%
Accionistas
Accionistas
Proporción
Madison Avenue Partners LP
19.02%
Weiss Asset Management
14.91%
Newtyn Management, LLC
9.51%
BlackRock Institutional Trust Company, N.A.
6.07%
Irenic Capital Management LP
5.52%
Other
44.96%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
59.93%
Investment Advisor
16.82%
Investment Advisor/Hedge Fund
11.60%
Individual Investor
4.71%
Research Firm
2.89%
Bank and Trust
0.23%
Pension Fund
0.19%
Venture Capital
0.04%
Insurance Company
0.03%
Other
3.56%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
288
48.24M
96.47%
-10.03M
2025Q1
306
49.02M
97.92%
-10.33M
2024Q4
307
49.22M
100.10%
-11.44M
2024Q3
311
50.46M
103.15%
-9.84M
2024Q2
312
51.86M
106.61%
-21.43M
2024Q1
304
56.26M
115.67%
-11.52M
2023Q4
301
56.96M
111.33%
-13.16M
2023Q3
314
59.36M
109.50%
-14.46M
2023Q2
331
61.03M
103.70%
-24.91M
2023Q1
329
68.16M
106.54%
-18.37M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Madison Avenue Partners LP
9.51M
19.02%
--
--
Mar 31, 2025
Weiss Asset Management
7.46M
14.91%
--
--
Mar 31, 2025
Newtyn Management, LLC
4.76M
9.51%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.04M
6.07%
-127.84K
-4.04%
Mar 31, 2025
Irenic Capital Management LP
2.76M
5.52%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
2.08M
4.16%
+77.48K
+3.87%
Mar 31, 2025
Park West Asset Management LLC
1.80M
3.61%
+11.26K
+0.63%
Mar 31, 2025
Winningham (Rick E)
1.31M
2.61%
-29.60K
-2.21%
Jun 23, 2025
Oasis Management Company Ltd.
1.12M
2.24%
+3.17K
+0.28%
Mar 31, 2025
State Street Global Advisors (US)
1.07M
2.13%
-155.69K
-12.74%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Virtus LifeSci Biotech Products ETF
2%
Invesco NASDAQ Future Gen 200 ETF
0.54%
ALPS Medical Breakthroughs ETF
0.37%
Global X Aging Population ETF
0.35%
iShares U.S. Pharmaceuticals ETF
0.2%
SPDR SSGA US Small Cap Low Volatility Index ETF
0.15%
iShares Micro-Cap ETF
0.09%
Invesco Nasdaq Biotechnology ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.06%
Avantis US Small Cap Equity ETF
0.05%
Ver más
Virtus LifeSci Biotech Products ETF
Proporción2%
Invesco NASDAQ Future Gen 200 ETF
Proporción0.54%
ALPS Medical Breakthroughs ETF
Proporción0.37%
Global X Aging Population ETF
Proporción0.35%
iShares U.S. Pharmaceuticals ETF
Proporción0.2%
SPDR SSGA US Small Cap Low Volatility Index ETF
Proporción0.15%
iShares Micro-Cap ETF
Proporción0.09%
Invesco Nasdaq Biotechnology ETF
Proporción0.06%
ProShares Ultra Nasdaq Biotechnology
Proporción0.06%
Avantis US Small Cap Equity ETF
Proporción0.05%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
